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Abstract 
Background: Dysregulation of microRNA-150 (miR-150) is commonly observed in solid tumor and has been 
reported to be involved in multiple important biological processes, such as cell proliferation, apoptosis, and metasta-
sis. Elevated miR-150 level was also detected in cervical carcinoma, whereas its function in cancer progression has not 
been studied yet.
Methods: The expression of miRNA-150 in cervical carcinoma was compared with normal cervical tissue and using 
qRT-PCR. The effects of miR-150 on cell cycle and apoptosis, as well as the expression of cycle- and apoptosis-related 
genes, were determined using flow cytometry, TUNEL assay, qRT-PCR, and Western blot, respectively. The direct target 
of miR-150 was confirmed using 3′ untranslated region (UTR) luciferase reporter assay.
Results: miR-150 promotes cervical cancer cell survival and growth, while the inhibition of miR-150 suppresses 
these actions. miR-150 also induced the cell cycle progression from G1/G0 to S phase, resulting in an enhancement 
of growth. Several cell cycle- and apoptosis-related genes, CyclinD1, p27, BIM, and FASL were modulated by miR-150. 
Moreover, miR-150 directly reduced the expression of FOXO4, which regulates the expression of CyclinD1, p27, BIM, 
and FASL, by targeting its 3′ UTR.
Conclusion: Taken together, our data demonstrated that elevated miR-150 targets FOXO4 expression and therefore 
regulates multiple genes expression, resulting in cervical cancer cell growth and survival.
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Background
Uterine cervical cancer is the third most common can-
cer, and is one of the leading causes of cancer mortality 
in young women worldwide [1–3]. Over 500,000 new 
cases and 274,000 death in global are reported each year 
[3]. Several treatment strategies, surgery, chemotherapy, 
radiotherapy and combined radio-chemotherapy were 
used in the clinic depending on the stage of cancer, and 
overall survival rate was improved. However, treatment 
failure and poor outcome occurs, especially in advanced 
stage of cervical cancer, due to the development of resist-
ance to radiotherapy and chemotherapy [4, 5]. Thus, 
identification of new potential therapeutic targets in 
cervical cancer is necessary for improving the treatment 
and prognosis.
MicroRNAs (miRNAs), endogenous non-coding RNA 
molecules, modulate multiple important biological pro-
cesses, including cell development, proliferation, differen-
tiation, apoptosis, signal transduction, and tumorigenesis, 
via regulation of genes expression [6, 7]. Dysregulation 
of miRNA expression is commonly observed in human 
malignancies and has been reported to promote the can-
cer progression. Aberrant expression of oncogenic and 
tumor suppressive miRNAs was detected in cervical cancer 
cell lines and they are required for tumor cell growth [8]. 
A study has identified 68 up-regulated miRNAs including 
miR-150 in the invasive cervical squamous cell carcinomas 
as compared with normal samples [9]. Upregulated miR150 
expression was also found in cervical intraepithelial neo-
plasia, a well-defined precursor stages of squamous cell 
carcinomas [10]. Indeed, higher expression of miR-150 was 
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found in many solid cancer types, such as gastric cancer, 
breast cancer, and non-small cell lung cancer, as well as cer-
vical cancer [11–13]. miR-150 promotes the proliferation 
of gastric cancer and lung cancer cells through negative 
regulation of the pro-apoptotic gene early growth response 
factor 2 (EGR2) and by targeting p53, respectively, suggest-
ing its pro-tumorigenic function [12, 14]. Multiple targets 
of miR-150 including mucins 4 (MUC4), zinc-finger E-box 
binding homeobox 1 (ZEB1), EGR2, p53, P2X purinocep-
tor 7 (P2X7), SRC kinase signaling inhibitor 1 (SRCIN1), 
BRI1-associated receptor kinase 1 (BAK1), and C-Myb, 
were also identified in several cancer cells and these targets 
are involved in the cell proliferation, apoptosis, and metas-
tasis [12, 13, 15–18]. However, the functions of miR-150 in 
the development of cervical cancer remain unclear.
In the present study, we demonstrate the elevated 
expression of miR-150 in cervical carcinoma as compared 
with para-carcinoma tissues and normal tissue from 
healthy donors, and that increased miR-150 expression is 
associated with the processed stages of cancer. Our data 
indicate that miR-150 targets FOXO4 and regulates mul-
tiple proliferation- and apoptosis-related proteins, there-
fore, promoting cervical cell survival and growth.
Methods
Patients and cell culture
Carcinoma and para-carcinoma tissues samples were col-
lected from patients who are newly diagnosed with cer-
vical carcinoma and normal cervical tissue was obtained 
from healthy donors. Patients and healthy donors were 
recruited from the second affiliated hospital of Chong-
qing Medical University and the second clinical medical 
institute of North Sichuan Medical College between July 
2012 and December 2014. Verbal informed consent was 
obtained from all the patients and donors. The design 
and implementation of this research was approved and 
documented by the clinical research ethical committee of 
Chongqing Medical University in Chongqing and North 
Sichuan Medical College in Nanchong. The human cervi-
cal carcinoma cell line C-33A and human embryonic kid-
ney cell line 293T was used in this study and maintained 
respectively in MEM and DMEM medium supplemented 
with 10 % heat-inactivated fetal bovine serum, glutamine, 
and antibiotics at 37 °C in 5 % CO2.
miRNA/RNA isolation and real‑time PCR
miRNA was isolated from tissues or cells using miRcute 
miRNA Kit (Tiangen, China) according to the manu-
facturer’s instructions. MiScript II RT kit (Qiagen, Ger-
many) was used for reverse transcription of miRNA. The 
expression of miR-150 was determined by miScript SYBR 
Green PCR Kit (Qiagen), using real-time PCR. The prim-
ers for miR-150 and U6 were purchased from Qiagen. Ct 
value of miR-150 was normalized to the U6 and the rela-
tive expression was carried out by 2−ΔΔCt method. Total 
RNA was isolated from C-33A cells using RNAprep pure 
Micro Kit (Tiangen) and reverse transcription of mRNA 
was performed using QuantScript RT kit (Tiangen) 
according to the manufacturer’s protocol. RT-PCR was 
performed with miScript SYBR Green PCR Kit (Qiagen) 
and specific primers using the ABI 7900TH Real-Time 
PCR System (Applied Biosystems, USA). The specific 
primer sequences for the genes were shown in Table  1. 
Relative mRNA expression was carried out using 2−ΔΔCt 
method after normalization to GAPDH.
Transient transfection
For transient transfection, miR-150 mimics (50 nM, Qia-
gen), miR-150 inhibitors (50 nM, Qiagen), or a negative 
control siRNA were used and transfected into C-33A 
cells using the Lipofectamine 2000 Transfection Regent 
(Invitrogen, USA) according to the manufacturer’s 
instructions.
Establishment of cell lines expressing miR‑150 mimics or 
inhibitors
Lentiviral vectors were used to establish stable cell 
lines expressing miR-150 mimics or inhibitors. Psin-
EF2-miR-150-IRES-GFP-puro expressing miR-150 
pre-miRNA was constructed using specific primers, 
5′-GCCGAATTCGCATAGGGTGGAGTGGGTGT-3′ 
(forward) and 5′-GCCGGATCCATAGAAACAGGTGTA 
CTTTG-3′ (reverse). The paired miR-150 inhibitors (for-
ward: 5′-GATCCCCCACTGGTACAAGGGTTGGGA 
GA-3′, reverse: 5′-AATTCTAAAAATCTCCCAACCCT 
TGTACCAGTG-3′) were inserted into pshRNA-copGFP 
Lentivectors. 293T cells were used to generate lentivi-
rus containing the sequences of miR-150 precursor or 
inhibitors. 293T cells were co-transfected with pMD2.G, 
pSPAX2, and pshRNA-copGFP-inhibitor or Psin-EF2-
miR-150-IRES-GFP-puro using Lipofectamine 2000 
Transfection Regent (Invitrogen). After 48  h, superna-
tant was collected and filtered using 0.22 um filter. Fil-
tered supernatant containing lentivirus was next used 
for transduction. C-33A cells were infected with lenti-
virus for 24 h and cultured with MEM medium includ-
ing puromycin (5  ng/mL). Expand cells were then used 
for further experiments and transduction efficiency 
was measured by a fluorescence microscope (Olympus, 
Japan). A control cell line transducted with empty vectors 
was also established after the same procedure.
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay
TUNEL assay with propidium iodide (PI) staining was 
used to identify apoptosis.C-33A cells transfected with 
Page 3 of 9Li et al. BMC Molecular Biol  (2015) 16:24 
miR150 mimics or inhibitors for 48  h were fixed and 
staining with fluorescein-conjugated dUTP (green) and 
PI (red). The apoptotic or living cells were observed by 
a fluorescence microscope (Olympus, Japan). This assay 
was independently repeated for 3 times.
Cell growth assay
C-33A cells (1  ×  104) expressing miR-150 mimics or 
inhibitors, as well as control cells, were cultured in a 
24-well plate for 4 days, and the cell number of the cells 
was determined every day. This assay was performed in 
triplicate and repeated in 3 independent experiments.
Cell cycle analysis
Cells were collected and washed with phosphate-buff-
ered saline (PBS), fixed in cold 70 % ethanol at 4 °C over-
night. Fixed cells were washed with PBS and incubated 
with RNase A (100 µg/ml) and PI (50 µg/ml) for 30 min. 
The DNA content was determined using a FACSCanto 
flow cytometer (BD Biosciences, USA) and the cell cycle 
profile was evaluated by FACS Diva Software (BD Bio-
sciences). This assay was repeated in 3 independent 
experiments.
Western blot
Whole cell lysates were extracted from cells suspended 
in radio immune precipitation buffer (Beyotime, China). 
Lysates were separated by electrophoresis on poly-
acrylamide gels containing 0.1 % sodium dodecyl sulfate 
(SDS-PAGE) and then transferred to polyvinylidene dif-
luoride membranes. The membranes were blocked with 
5 % non-fat milk in Tris Buffer Saline Tween 20 (TBST) 
buffer. The blots were incubated with the primary anti-
body and exposed to HRP-conjugated secondary anti-
body. The bands on the membrane were visualized and 
captured using the ECL reagent (Beyotime) and X-ray 
films, respectively. The pixel densities of proteins were 
quantified using ImageJ 1.47 software. Antibodies 
against to GAPDH, CyclinD1, p27, p-pRb, FasL, and 
Bim, as well as horseradish peroxidase (HRP)-linked 
anti-mouse and -rabbit IgG, were bought from Beyo-
time and used in this study.
Luciferase reporter assay
Wild type or mutant 3′ untranslated region (UTR) of 
FOXO4 containing the putative binding sites for miR-
150 were subcloned into psiCHECK-2 Vectors. The 
constructed plasmids were transfected into C-33A cells 
or cells expressing miR-150 mimics or inhibitors using 
Lipofectamine 2000 Transfection Regent (Invitrogen). 
After 48 h, the luciferase activity in cell lysates was eval-
uated using the Dual-Luciferase Reporter Assay system 
according to the manufacturer’s instructions (Promega, 
USA).
Statistical analysis
Statistical significance for the experiments was deter-
mined using the Student’s t test or One-way ANOVA. 
p <0.05 was regarded as statistically significant. The stand-
ard deviation was demonstrated by bar in the figures.
Results
Elevated expression of miR‑150 in cervical cancer
miR-150 dysregulation has been found in several solid 
tumors including gastric cancer, breast cancer, and lung 
cancer [13], whereas the relationship between miR-150 
expression and cervical cancer has not been well studied. 
Here, we first compared the miR-150 expression in cervi-
cal carcinoma and para-carcinoma tissues obtained from 
10 patients and significantly higher expression of miR-
150 was observed in carcinoma cells (Fig.  1a). Moreo-
ver, the expression of miR-150 in the cervical carcinoma 
of cancer patients was significantly higher than that in 
normal cervical tissue from healthy donors (Fig.  1b). 
The level of miR-150 expression in cervical tissue was 
increased along with the stage progression and a 25 times 
higher miR-150 expression was found in the advanced 
stage of cervical cancer (Fig. 1c). A human cervical carci-
noma cell line C-33A also expressed a high level of miR-
150 (Fig.  1c) as compared with normal donors. These 
results suggest a close relationship between miR-150 
expression and cervical carcinoma.
miR‑150 promotes the survival of cervical cancer cells
miR-150 has been reported to be involved in cancer cell 
growth and apoptosis and we next determined the func-
tions of miR-150 in cervical carcinoma cells. C-33A cells 
were transfected with siRNA control, miR-150 mimics or 
inhibitors and cultured in serum free medium for 48  h. 
Thereafter, the apoptosis in these cells were determined 
by TUNEL assay. As shown in Fig. 2a, b, clearly decrease 
of apoptosis (green) was observed in the cells transfected 
Table 1 Primer sequences used for RT-PCR
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with miR-150 mimics, whereas the miR-150 inhibitors 
induced more apoptotic cells (TUNEL+ cells), indicating 
the positive function of miR-150 in cervical carcinoma 
cell survival.
miR‑150 facilitates cervical cancer cell growth
To further investigate the roles of miR-150 in cervical 
carcinoma cells, two sub-cell lines of C-33A consistently 
expressing miR-150 mimics or inhibitors and a control 
cell line were established. Overexpression of miR-150 in 
the cell lines expressing miR-150 mimics was confirmed 
by RT-PCR (Fig. 3a). The growth of these three cell lines 
were determined next and the cells expressing miR-150 
mimics were growing faster than the control and the cells 
expressing miR-150 inhibitors (Fig. 3b), whereas the cells 
expressing miR-150 inhibitors were growing slower than 
the control (Fig.  3b). Cell cycle of these three cell lines 
was evaluated next and higher level of cell at S phase was 
observed in miR-150 mimic-expressing cells (Fig. 3c, d). 
Overexpression of miR-150 inhibitors induces more cell 
cycle arrest at the G1/G0 phase (Fig. 3c, d). These find-
ings indicate that miR-150 promotes the cervical cancer 
cell growth and cell cycle progression from the G1/G0 to 
S phase.
miR‑150 regulates the expression of proteins related to cell 
proliferation and apoptosis in cervical cancer cells
Since miR-150 promotes the survival and cell cycle 
progression, expression of several related proteins was 
determined next in the three sub-cell lines. mRNA 
expression of two cell cycle-related genes CyclinD1 
and p27, as well as two cell apoptosis-related genes 
Fig. 1 Cervical cancer cells express higher level of miR-150. a miR-150 expression was measured in cervical carcinoma and para-carcinoma tissues 
from the patients (n = 10) by RT-PCR. The miR-150 expression in cervical carcinoma tissue normalized to that in paired para-carcinoma tissues is 
presented by a histogram. b miR-150 expression in cervical tissue from healthy donors (normal, n = 13) or in cervical carcinoma tissue from patients 
(n = 108) was determined by RT-PCR and the relative miR-150 expression is presented after normalization to healthy donors. c The miR-150 expres-
sion in cervical tissue from healthy donors (n = 13) or in cervical carcinoma tissue from 62 patients at different stages (23 at grade II, 19 at grade III, 
20 at grade IV), as well as in a human cervical carcinoma cell line C-33A, was evaluated by RT-PCR
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FASL and BIM, was measured by qRT-PCR. miR-
150 mimics significant upregulated CyclinD1 mRNA 
expression and reduced the mRNA expression of 
p27, FASL, and BIM (Fig.  4a, b). In contrast, miR-
150 inhibitors decreased the CyclinD1 expression 
and increased the expression of p27, FASL, and BIM 
(Fig. 4a, b). Consistent with mRNA results, the protein 
level of CyclinD1 was increased by miR-150 mimics 
and reduced by miR-150 inhibitors, whereas protein 
levels of p27, FASL, and BIM were reduced by miR-150 
mimics and increased by miR-150 inhibitors (Fig.  4c, 
d). Moreover, the phosphorylated pRb, a regulator of 
cell cycle, was increased by miR-150 and decreased by 
miR-150 inhibitors (Fig. 4c).
miR‑150 targets FOXO4 in cervical cancer cells
miRNA plays important roles in cell proliferation, dif-
ferentiation, apoptosis and other biological processes 
by targeting the 3′UTR site of multiple genes, therefore 
regulating their transcription. FOXO4 is a predicted tar-
get gene of miR-150 (http://www.microrna.org) and we 
found significant downregulation of FOXO4 in C-33A 
cells expressing miR-150 mimics and the upregulation 
of FOXO4 in the cells expressing miR-150 inhibitors 
(Fig.  5a). To confirm that miR-150 directly targets the 
3′UTR of FOXO4, two luciferase reporter plasmids con-
taining wild type or mutant 3′ UTR were constructed 
(Fig.  5b). In C-33A cells overexpressing miR-150, the 
luciferase activity regulated by wild type 3′UTR of 
FOXO4 was significantly reduced and miR-150 inhibi-
tors increased the luciferase activity (Fig. 5c). Moreover, 
miR-150 mimics and inhibitors did not affect luciferase 
activity regulated by mutant 3′UTR of FOXO4 (Fig. 5c), 
indicating that miR-150 directly targets FOXO4.
Discussion
Although a variety of altered miRNAs have been identi-
fied in cervical carcinomas, their underlying functions 
and mechanisms in cervical cancer development have 
not been fully studied. Among 70 dysregulated miRNAs 
identified in cervical carcinomas, miR-150 is upregulated 
by above 2.5 times as compared with healthy donors [9]. 
Our results add further information about the correla-
tion between increased miR-150 and cervical cancer pro-
gression. Importantly, we observed pro-cancer effects of 
miR150 as miR-150 promotes cervical cancer growth and 
survival. Here, FOXO4 is identified as a direct target of 
miR-150 which also regulates the expression of CyclinD1, 
p27, BIM, and FASL, as well as the phosphorylation of 
pRb. Based on the fact that activated FOXO4 directly or 
indirectly regulates the expression of CyclinD1, p27, BIM, 
and FASL [19–24], we propose a hypothesis that miR-150 
induces the transcriptional arrest of FOXO4 by binding 
to 3′-UTR of its mRNA, therefore reduces p27, FASL, 
BIM and pRb activation, and increases CyclinD1, finally 
leading to cell cycle progression and survival (Fig.  5d). 
Our findings highlight the involvement and crucial role 
of miR-150 in cervical cancer development.
It has been well documented that aberrant expression 
of miR-150 is associated with cancer development and 
progression through regulating oncogenes or tumor sup-
pressor genes [13, 25–27]. Different features of miR-150 
expression in different solid cancer types have been shown 
Fig. 2 miR-150 promotes the survival of cervical carcinoma cells. a 
C-33A cells were transfected with siRNA control, or miR-150 mimics 
(miR-150) or inhibitors for 48 h and the apoptosis was determined 
by TUNEL assay and PI staining. Representative pictures of the TUNEL 
assays are presented. b The percentage of TUNEL-positive cells was 
counted and presented by a histogram. Mean values ± standard 
deviation (SD) for 3 independent experiments is shown
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in many studies. Decreased level of miR-150 has been 
found in pancreatic cancer [28], esophageal cancer [16], 
colorectal cancer [29–31], and liver cancer [32, 33], while 
elevated expression of miR-150 has been found in gastric 
cancer [12, 34], breast cancer [18, 35], and non-small cell 
lung cancer [14, 17, 36]. Previous studies [9, 10], together 
with our finding here, confirm that miR-150 is upregulated 
in cervical cancer. Moreover, our data demonstrated that 
increased miR-150 expression is also correlated with the 
processed stages of cervical cancer and revealed a novel 
role of miR-150 in cervical cancer progression, which 
involves regulation of cell cycle and apoptosis.
Pro-survival and -growth functions of miR-150 with 
distinct mechanisms have been demonstrated in breast, 
gastric and lung cancer cells [12, 14, 18]. Huang et al. has 
shown that miR-150 overexpression promotes human 
breast cancer cell growth, clonogenicity, and reduces 
apoptosis by targeting the pro-apoptotic purinerigic 
P2X7 receptor and that reduction of miR-150 suppresses 
tumor growth in xenograft breast tumor mice [18]. 
Ectopic expression of miR-150 increases the growth of 
gastric cancer cells and promotes tumorigenesis in  vivo 
[12]. Inhibition of miR-150 in lung cancer cells effectively 
suppresses cell proliferation and promotes apoptosis [14]. 
Here, miR-150 overexpression in cervical cancer cells 
promotes cell growth and survival, while miR-150 inhi-
bition delays cell proliferation and induces more apopto-
sis. Moreover, miR-150 reduces the mRNA and protein 
expression of two pro-apoptotic genes BIM and FASL, 
suggesting that miR-150 promote cell survival through 
downregulating these genes. Furthermore, miR-150 
enhances the cell cycle progression from the G1/G0 to 
S phase which is related to the decrease of p27 and the 
increase of CyclinD1.
It has been identified that miR-150 targets the 3′UTR 
of multiple genes which play important roles in cell pro-
liferation, clonogenicity, invasion, intercellular adhesion, 
and apoptosis. In gastric cancer cells, miR-150 promotes 
Fig. 3 miR-150 promotes the growth of cervical carcinoma cells. a The expression of miR-150 in non-transduction C-33A cells (mock) or stable cells 
after transduction with control virus (control) or virus containing miR-150 mimics (miR-150) was analyzed by RT-PCR. The bar represents 3 independ-
ent experiments. b Same number of C-33A cells expressing miR-150 mimics or inhibitors, or empty vector-transducted C-33A cells (control) were 
seeded into 24-well plate and cultured for 4 days. The cell number was counted every day. Mean values ± SD for 3 independent experiments is 
shown. c The cell cycle analysis in the three stable C-33A sub-cell lines was performed after PI staining and representative DNA content profiles of 
cell cycle are presented. d The percentages of cells in different cell cycle stages from 3 independent experiments were analyzed and presented by a 
histogram
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cell survival by repressing the transcription of EGR2, a 
pro-apoptotic gene [12]. miR-150 also targets the 3′UTR 
of p53 and thus regulates its expression, leading to cell 
survival [14]. 3′UTR of pro-apoptotic purinergic P2X7 
is targeted by miR-150 in breast cancer cells [18, 35]. 
Our work identified FOXO4 as a novel target of miR-
150 as miR-150 suppressed the transcriptional process 
of FOXO4 through targeting the 3′UTR of its mRNA. 
FOXO4, a member of the class O of forkhead box tran-
scription factors (FOXOs), is an important downstream 
target of the insulin-phosphatidylinositol 3-kinase 
(PI3K)–serine–threonine kinase AKT/protein kinase B 
(AKT/PKB) signaling pathway which can protect cells 
against apoptosis [19]. Enforced FOXO4 activity induces 
apoptosis through regulation of various pro-apoptotic 
genes, such as FASL, BIM, Bcl-6, and PUMA, and mod-
ulates cell cycle progression through influencing p27, 
p130Rb2, CyclinD1, and CyclinG2 [19]. Since miR-150 
overexpression modulates the expression of CyclinD1, 
p27, FASL, and BIM, it is possible that these regulation is 
caused by miR-150-mediated FOXO4 targeting (Fig. 5d).
Conclusion
In summary, our results demonstrate the important 
role of elevated miR-150 in cervical cancer progression 
and reveal that miR-150 promotes cervical cancer cell 
growth and survival by targeting FOXO4. Moreover, our 
data also suggest that miR-150 can be used as a potential 
Fig. 4 miR-150 affects the expression of proteins involved in cell proliferation and apoptosis. a The mRNA expression of cell cycle-related genes 
CyclinD1 and p27 in the three C-33A sub-cell lines (control, miR-150, miR-150 inhibitor) was measured by RT-PCR. Mean values ± SD for 3 independ-
ent experiments is shown. b The mRNA expression of apoptosis-related genes FASL and BIM in these three sub-cell lines from 3 independent 
experiments was evaluated by RT-PCR. Mean values ± SD for 3 independent experiments are shown. c The expression of Cyclin D1, p27, GAPDH, 
and phophorylated pRb (p-pRb) in the sub-cell lines was determined by western blot, and the pixel densities of these proteins were analyzed 
and presented by histograms (bottom). Mean values ± SD for 3 independent experiments is shown. d The expression of FASL, BIM, and GAPDH in 
the sub-cell lines was determined by western blot, and the pixel densities of these proteins were analyzed from 3 independent experiments and 
presented by histograms (bottom)
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therapeutic target which may improve the treatment of 
cervical cancer.
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